Eukarÿs

Startup

Eukarÿs multiplies by 5x to 7x the biomanufacturing yields in mammalian cells (CHO, HEK-293...) thanks to C3P3: off-the-shelf technology, CAPEX-free and easy-to-deploy solution, compatible with any industrial process.  

Universal platform: all antibodies (including multispecific), recombinant proteins, ADC, virus-like-particles, RNA viruses... 

Three major benefits:  

• drug development is accelerated by up to 6 months 

• costs and investments are drastically reduced: less batches, less re-agents, less equipments 

• hard-to-express biologics are easier to produce. 

   

C3P3 relies on the very first multifunctional RNA polymerase: it creates within cells in culture a completely new mRNA synthesis pathway, which comes in addition to the one of the host-cells, and is dedicated to the Genes Of Interest. Within the cells, C3P3 is producing much more mRNA-of-interest, and most importantly is maturing it (performing post-transcriptional modifications such as the capping and poly-adenylation). As a result, the cells are producing much more proteins-of-interest, the biomedicine. 

Eukarÿs is the only non-US company that has been selected by BARDA in 2025 to enter its Vanguard accelerator program dedicated to key enabling technologies.  

Eukarÿs has also won the Prix Galien MedStartup and the Sanofi Golden Ticket.